Back |
home / stock / gnftf / gnftf message board
Subject | By | Source | When |
---|---|---|---|
Genfit: Refuting Bearish Arguments About Genfit's Results - | Wildbilly | investorshub | 04/07/2015 12:58:01 AM |
Genfit: Misunderstandings And Propaganda About Phase 2b Results | Wildbilly | investorshub | 03/31/2015 11:35:37 PM |
Conference call 2:30 EDT Thurs. 3/26/2015 | Wildbilly | investorshub | 03/26/2015 6:19:21 PM |
Genfit to conduct large liver drug trial despite | Wildbilly | investorshub | 03/26/2015 6:12:02 PM |
Genfit phase-2 NASH trial misses primary endpoint, | Wildbilly | investorshub | 03/26/2015 5:30:40 PM |
Genfit Next Up In The M&A Rumor Mill | Wildbilly | investorshub | 03/25/2015 2:56:49 AM |
FDA grants Fast Track designation to GFT505 in NASH | Wildbilly | investorshub | 03/25/2015 2:24:45 AM |
News, Short Squeeze, Breakout and More Instantly...
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the inclusi...
Ipsen’s Iqirvo ® (elafibranor) 80 mg tablets receives U.S. FDA accelerated approval as a first-in-class treatment for Primary Biliary Cholangitis (PBC) First-ever drug developed in-house by GENFIT to achieve U.S. FDA’s approval GENFIT is eligible to ...
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 29, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today detailed its presence ...